Juno Therapeutics Inc

Most Recent

  • uploads///Yescarta
    Company & Industry Overviews

    What Else Could Drive Gilead’s Long-Term Growth?

    In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

    By Daniel Collins
  • uploads///Celgene acquires
    Company & Industry Overviews

    Celgene to Acquire Juno Therapeutics

    On January 22, 2018, Celgene and Juno Therapeutics announced a merger agreement in which the former will acquire the latter’s business.

    By Daniel Collins
  • uploads///Oncology Pipeline
    Company & Industry Overviews

    An Overview of Celgene’s Hematology and Oncology Pipeline

    In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    How Are XBI’s Holdings’ Moving Averages Trending?

    On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Holdings: How Are Their Moving Averages Trending?

    The iShares Nasdaq Biotechnology ETF (IBB) has 189 stocks in its portfolio. As of June 6, 2016, 87% of IBB’s stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB’s Mid-Cap Stocks: Kite Pharma Drug Gets Orphan Drug Status

    IBB’s mid-cap holding Kite Pharma (KITE) rose by 3.3% on the news of the FDA granting orphan drug status to Kite’s KTE-C19.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study

    The mid-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 1% on April 20, 2016. Within XBI, Ionis Pharmaceuticals’ stock closed at $43.62 on the day.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Mid-Cap News: Look Who Took a Beating on March 23

    Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.

    By Peter Neil
  • uploads///Graph Part  OCt
    Company & Industry Overviews

    Analyzing Juno Therapeutics’ Performance until September 2015

    Juno Therapeutics (JUNO) is a mid-cap stock with a market cap of ~$4.75 billion. The stock rose by 8.6%. It outperformed all of the biotech stocks.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Kite Pharma and Juno Therapeutics Led Biotechnology Sector

    Kite Pharma and Juno Therapeutics led the Biotechnology group of the SPDR S&P Biotechnology ETF (XBI) for the week ending September 11. Kite Pharma and Juno Therapeutics rose 21.94% and 19.78%, respectively.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.